Mason Street Advisors LLC Purchases 5,072 Shares of Baxter International Inc (NYSE:BAX)

Mason Street Advisors LLC raised its position in shares of Baxter International Inc (NYSE:BAX) by 7.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,738 shares of the medical instruments supplier’s stock after acquiring an additional 5,072 shares during the period. Mason Street Advisors LLC’s holdings in Baxter International were worth $6,362,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. 1 North Wealth Services LLC bought a new stake in Baxter International during the third quarter valued at about $27,000. Personal Wealth Partners bought a new stake in shares of Baxter International in the second quarter valued at about $29,000. TRUE Private Wealth Advisors bought a new stake in shares of Baxter International in the second quarter valued at about $29,000. Old North State Trust LLC bought a new stake in shares of Baxter International in the third quarter valued at about $31,000. Finally, Evolution Wealth Advisors LLC bought a new stake in shares of Baxter International in the second quarter valued at about $32,000. Institutional investors own 83.19% of the company’s stock.

In related news, Director James R. Gavin III sold 7,950 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $87.63, for a total value of $696,658.50. Following the completion of the transaction, the director now owns 40,932 shares of the company’s stock, valued at $3,586,871.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew Frye sold 3,332 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $88.00, for a total transaction of $293,216.00. Following the completion of the transaction, the senior vice president now directly owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The disclosure for this sale can be found here. Insiders sold 17,396 shares of company stock valued at $1,528,575 in the last three months. Company insiders own 0.70% of the company’s stock.

NYSE:BAX traded up $1.39 during mid-day trading on Tuesday, hitting $80.25. The company’s stock had a trading volume of 2,941,249 shares, compared to its average volume of 3,716,047. Baxter International Inc has a fifty-two week low of $61.40 and a fifty-two week high of $89.93. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $40.08 billion, a price-to-earnings ratio of 26.31, a P/E/G ratio of 2.02 and a beta of 0.97. The stock has a fifty day moving average of $83.72 and a 200-day moving average of $82.14.

BAX has been the subject of several research reports. Royal Bank of Canada set a $87.00 target price on shares of Baxter International and gave the company a “hold” rating in a research note on Friday, July 26th. Deutsche Bank initiated coverage on shares of Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 target price for the company. ValuEngine cut shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. Finally, Raymond James increased their target price on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $90.14.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: Diluted Earnings Per Share

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.